BECTON DICKINSON & CO Business Intelligence Report
BECTON DICKINSON & CO Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
Becton Dickinson & Co (BDX) has demonstrated a transformative decade, characterized by large-scale strategic acquisitions—most notably Bard and CareFusion—that have structurally scaled the business from a $4B revenue profile to over $21B. The company maintains a dominant position in medical supplies, devices, and laboratory equipment, serving as a critical infrastructure provider for global healthcare. While the aggressive inorganic expansion led to significant fluctuations in net income and diluted EPS between 2016 and 2020, the business has successfully integrated these assets to stabilize…
Key Changes in FY2026
Over the last decade, BD has undergone a massive transformation from a steady-state medical supplies firm into a high-tech medical technology powerhouse. The 2017 acquisition of C.R. Bard marked the most significant pivot, adding high-margin interventional platforms in oncology and vascular health. Subsequent years focused on deleveraging and digitizing the 'BD Excellence' operating system to drive margin expansion. The 2022 spin-off of Embecta removed a slow-growing commodity business, allowing management to concentrate capital on the BD Medical and BD Life Sciences segments. Recently, the company has pivoted toward 'BD2025' strategy goals, emphasizing AI-driven diagnostics and pharmacy automation. The evolution shows a clear shift up the value chain toward high-switching-cost clinical…
Management Commentary
Management has demonstrated strong execution in integrating complex global organizations, a feat evidenced by the stabilization of operations post-2021. The leadership team provides clear guidance through their multi-year strategic frameworks, focusing on 'Simplify, Empower, and Grow.' There is a visible effort to move the portfolio toward higher-growth categories like interventional medicine and biosciences. However, the period of 2018-2020 saw significant earnings volatility that tested management's credibility regarding synergy timelines. The recent performance in 2024-2025, showing revenue growth and rebounding EPS, suggests that the executive team has successfully navigated the integration risks and is now delivering on the promise of a more diversified and resilient enterprise.
Financial Highlights
The financial trajectory of BDX shows a clear bifurcation between its legacy scale and the post-acquisition era starting in 2021. Revenue has grown at a 10-year CAGR exceeding 15% due to consolidation, though organic growth is more modest in the mid-single digits. Profitability has been historically volatile; Net Income margins dipped into negative territory in 2018 due to acquisition-related charges but have since stabilized around 7-9%. The recent uptick in Revenue to $21.84B in 2025 indicates a successful recovery from post-pandemic diagnostic shifts. Return on Equity (ROE) remains under pressure relative to historical highs due to a significant increase in the equity base, which jumped from $7.6B in 2016 to over $25B currently. Operating income growth remains steady, suggesting that…
Major Opportunities
- Critical market position in medical delivery and diagnostics
- Significant revenue scale expansion over 10 years
- Consistent positive operational cash flow generation
Major Risks
- Significant margin compression post-2021
- High intangible asset balance on the balance sheet
- Regulatory risks regarding product recalls (e.g., Alaris pumps)
About BECTON DICKINSON & CO's Annual Report & Financial Performance
The latest BECTON DICKINSON & CO annual report (FY2026) is the company's flagship annual disclosure, filed with SEC EDGAR. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this BECTON DICKINSON & CO research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
BECTON DICKINSON & CO — Frequently Asked Questions
Explore more BECTON DICKINSON & CO research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.